Navigation Links
Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial,of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable,Cytogenetics at EHA Meeting

le cytogenetics have traditionally not responded well to induction chemotherapy, so the activity of Cloretazine(R) (VNP40101M) in this setting is particularly encouraging."

Ann Cahill, Vion's Vice President, Clinical Development, said, "Elderly AML patients with unfavorable cytogenetics have few available treatment options." Ms. Cahill added, "Our ongoing pivotal Phase II trial is designed to confirm the activity of Cloretazine(R) (VNP40101M) in poor-risk patients, including those with unfavorable cytogenetics."

A pivotal Phase II clinical trial in elderly patients with de novo poor- risk AML is underway currently in over 20 sites in North America and Europe. Completion of accrual to this trial is expected in June or July 2007.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer is also underway. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. In preclinical studies, Vion is also evaluating VNP40541, a hypoxia-selective compound, and hydrazone compounds. The Company also is seeking development partners for TAPET(R), its modified Salmonella vector used to deliver anticancer agents directly to tumors. For additional information on Vion and its product development programs, visit the Company's Internet web site at www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subjec
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Tobramycin is a traditional antibiotic whose eye drop ... the treatment of potential infection or inflammation caused by ... China are able to produce tobramycin, among ...
(Date:8/28/2015)... Aug. 28, 2015 ... addition of the "Investigation Report on China,s ... offering. Developed by Novo Nordisk, insulin ... an important drug for the treatment of diabetes. ... fast- acting insulin analog, starts working fast and ...
(Date:8/28/2015)... -- IP Shakti, LLC, today announced that it has changed its ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... signifies our transformation into a company focused on patent claim ... claim validity." ... platform, the Company commenced a corporate re-branding initiative in order ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2
(Date:8/28/2015)... ... 28, 2015 , ... For Dallas, the time is nearing for the annual ... Tenet Health. , The American Heart Association hosts their well-known Heart Walk to raise ... together, a difference can be made. Walkers can participate in the cause and someone ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... As ... from Merz, received FDA clearance for results that last for two years, the ... exciting news for patients who are looking for a long-lasting, effective solution for their ...
(Date:8/28/2015)... , ... August 28, 2015 , ... On May 30th, ... joined as sponsor of the “Music With A Mission” benefit concert in Mendon, IL. ... event was to raise money to support music education programs in the underfunded local ...
(Date:8/28/2015)... ... August 28, 2015 , ... Saint Petersburg, FL ... with zero fat, carbs, sugar, gluten, lactose or caffeine in a convenient 2 ... 2015 SupplySide CPG Editor’s Choice Awards. , Five consumer packaged goods (CPG) products ...
(Date:8/28/2015)... ... August 28, 2015 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices, recently released Visio Stencils for the ... HP ProLiant Gen9, EMC VNX Series , Super Micro Computer SuperStorage, Hitachi Data ...
Breaking Medicine News(10 mins):Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 2Health News:Altima Updates NetZoom™ Visio® Stencil Library for Cisco, HP, and EMC Devices 3
... , , BOTHELL, Wash., Sept. ... ) announced today that on September 15, 2009, the NYSE ... with respect to its previously disclosed listing deficiency as set ... Such deficiency relates to the Company,s failure to maintain stockholder,s ...
... SOMERSET, N.J., Sept. 18 TeamStaff, Inc. ... healthcare and administrative staffing services, today announced that on September ... Department of The Nasdaq Global Market (Nasdaq) stating that for ... has not maintained a minimum market value of publicly held ...
... , CHICAGO, Sept. 18 As economic, ... in Illinois, the state,s leading provider of addiction treatment services ... people who can,t afford expensive clinics but also fail to ... Gateway Foundation Inc., a 41-year-old non-profit organization, serves more than ...
... stems from access to alcohol or feelings of isolation remains ... study suggests there,s a link between suicide and rural communities ... research doesn,t confirm that more bars mean more suicides because ... those who commit suicide, about 20 percent are alcoholics, according ...
... SAN FRANCISCO, Sept. 18 VIA Pharmaceuticals, Inc. ... the development of compounds for the treatment of cardiovascular and ... received a deficiency letter from the NASDAQ Stock Market stating ... $1.00 per share bid price requirement for continued listing, as ...
... , , BROOMFIELD, Colo., Sept. 18 Accera, ... diseases, today announced today that it will present at the UBS ... , , Steve Orndorff, Ph.D., founder, president and ... on Axona (TM) on Monday, September 21 at 11:30 a.m. ...
Cached Medicine News:Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 2Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 3Health News:SCOLR Pharma, Inc. Receives Notice from NYSE Amex LLC Regarding Compliance Plan and Listing Standards 4Health News:TeamStaff Receives Nasdaq Deficiency Notice Related to the Market Value of Its Publicly Held Shares 2Health News:TeamStaff Receives Nasdaq Deficiency Notice Related to the Market Value of Its Publicly Held Shares 3Health News:Gateway Responding To Increased Need for Treatment Among Middle-Income Substance Abusers 2Health News:Suicides Higher in Rural Areas With Bars 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 2Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 3Health News:VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ 4Health News:Accera, Inc. to Present at UBS Global Life Sciences Conference 2
Inquire...
Inquire...
Inquire...
... Optimal for Subcellular Fractionation, Proteins ... g (30,000 rpm) with fixed-angle ... 0.25 up to 85 mL ... C to 40° C • ...
Medicine Products: